Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
CosentyxⓇ showed steady growth, preparing for LCM
Sales evolution
USD m, % cc
Ex-US
US
+7% cc
1 GROWTH
Cosentyx E
AZ
K
K
L
Maintaining competitive position across geographies
"
>875k patients treated across 5 indications since launch
1,247
1,274
494
532
■
US: Solid volume growth, offset by revenue deductions
Europe: Leading originator biologic in PsO and SpA
Future growth drivers
☐
Volume-driven growth across core indications
Expanding geographical reach including China
Hidradenitis Suppurativa regulatory file submitted to FDA and EMA
IV regulatory file expected to be submitted in Q4 to FDA
753
742
☐
☐
Additional life cycle management including giant cell arteritis
Q3 2021
Q3 2022
PSO Psoriasis SpA Spondyloarthritis IV-intravenous
7 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation